Skip to main content
DSGN logo

Design Therapeutics, Inc.

DSGNNASDAQHealthcareBiotechnology

$10.31Today:- (-)1Y +82.58%

As of Oct 16, 2026 close

Market cap
$655.06M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.28$17.25
Volume (live)
-
Avg. volume (3M)
708.85K

Design Therapeutics, Inc. (DSGN) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Design Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 6 professional research analysts

Consensus Rating

Buy
Based on 6 unique analysts
Medium Confidence∞:1 Buy/Sell

Average Price Target

$26.09
+153.06% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest DSGN Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Unknown Analyst
Leerink Partners
BuyReiterates
$22.00
Tianqi Hang
Wells Fargo
BuyInitiates
$26.00
Unknown Analyst
Wells Fargo
BuyInitiates
$26.00
Unknown Analyst
Cantor Fitzgerald
BuyMaintains
$40.54
Adam Vogel
Craig-Hallum
BuyMaintains
$22.00
Leonid Timashev
RBC Capital
BuyMaintains
$20.00

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 13, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for DSGN?

The analyst consensus rating for DSGN is Buy, based on the latest ratings from 6 analysts over the last 90 days.

What is the average price target for DSGN?

The average 12-month price target for DSGN is $26.09, representing an upside of 153.1% from the Oct 16, 2026 close of $10.31.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.